Resource Summary Report

Generated by dkNET on Aug 7, 2026

Mouse Anti-CD3 Monoclonal Antibody, Phycoerythrin Conjugated, Clone HIT3a

RRID:AB_395746
Type: Antibody

Proper Citation

BD Biosciences Cat# 555340, RRID:AB_395746

Antibody Information

URL: http://antibodyregistry.org/AB_395746

Proper Citation: BD Biosciences Cat# 555340, RRID:AB_395746

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD3 Monoclonal Antibody, Phycoerythrin Conjugated, Clone HIT3a

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: HIT3a

Antibody ID: AB_395746

Vendor: BD Biosciences

Catalog Number: 555340

Record Creation Time: 20250819T205243+0000

Record Last Update: 20250819T210707+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD3 Monoclonal Antibody, Phycoerythrin Conjugated, Clone HIT3a.

No alerts have been found for Mouse Anti-CD3 Monoclonal Antibody, Phycoerythrin Conjugated, Clone HIT3a.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Boyer T, et al. (2026) Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a membrane-bound TGF-?1-dependent mechanism. Cell reports, 45(7), 117568.

Li B, et al. (2026) Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy. iScience, 29(5), 115578.

Garza B, et al. (2025) Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific and Neo-antigens in Follicular Cell-derived Thyroid Cancers. The Journal of clinical endocrinology and metabolism.

Decker AH, et al. (2025) Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis. iScience, 28(7), 112957.

Giraud J, et al. (2024) THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. Cell reports, 43(2), 113773.

Becker AMD, et al. (2024) Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. Cell reports. Medicine, 5(2), 101386.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer immunology research, 12(10), 1421.

van der Heijden S, et al. (2023) In vitro expansion of Wilms' tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells. STAR protocols, 4(1), 102053.

Arandjelovic P, et al. (2023) Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice. Cell reports. Medicine, 4(9), 101178.

Yang B, et al. (2022) Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell reports. Medicine, 3(12), 100856.

Doss PMIA, et al. (2021) Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity. Cell reports, 34(10), 108833.

Picarda E, et al. (2019) Cross-Reactive Donor-Specific CD8+ Tregs Efficiently Prevent Transplant Rejection. Cell reports, 29(13), 4245.

Chao MP, et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell stem cell, 20(3), 329.